

CLAIMS

1. Use of an eIF4E binding agent in therapy.
2. Use according to claim 1 for the induction of
5 programmed cell death.
3. Use according to either of claims 1 or 2 wherein
the agent is a peptide or peptidemimetic.
- 10 4. Use according to claim 3 wherein said peptide
comprises the sequence:
YxxxxLØ [SEQ ID NO: 4]
wherein x is a variable amino acid and Ø is Leu, Met or
Phe;
15 or a fragment or derivative thereof.
5. Use according to claim 4 wherein said peptide
comprises the sequence:
(K/R)xxYxxxx(F/Q)L(L/M) [SEQ ID NO: 5].
- 20 6. Use according to claim 5 wherein said peptide
comprises the sequence:
KKRYDREFLLGF [SEQ ID NO: 1],
RVRYSQQLLDL [SEQ ID NO: 2], or
25 RIIYDRKL(L/M) [SEQ ID NO: 3].
7. Use according to any of claims 3 - 6 wherein said
peptide is 7 -25 amino acids in length.

8. Use of a peptide comprising sequence:

YxxxxLØ [SEQ ID NO: 4] wherein x is a variable amino acid and Ø is Leu, Met or Phe;

or fragment or derivate thereof in the manufacture of a
5 medicament for therapy, more particularly for inducing cell death.

9. Use according to claim 8 wherein the medicament is used to induce cell death in tumour cells.

10

10. Use of a polynucleotide fragment encoding a peptide comprising sequence:

YxxxxLØ [SEQ ID NO: 4] wherein x is a variable amino acid and Ø is Leu, Met or Phe.